Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 10/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 2/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.34 |
| ▸ | IL2 | P60568 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2086786 | 0.88 | TRPV1 (0.40) | NR3C1TRPV1 | |
| SCHEMBL2084824 | 0.87 | GPR119 (0.42) | NR3C1GAAMAPT | |
| SCHEMBL2055582 | 0.85 | MAPT (0.35) | NR3C1TRPV1MGAMGAASI | |
| SCHEMBL2055577 | 0.85 | NR3C1 (0.39) | NR3C1TRPV1MGAMGAASI | |
| SCHEMBL2055576 | 0.85 | NR3C1 (0.37) | NR3C1TRPV1MGAMGAASI | |
| SCHEMBL2055578 | 0.84 | NR3C1 (0.37) | NR3C1TRPV1MGAMGAASI | |
| SCHEMBL4114463 | 0.82 | NR3C1 (0.37) | NR3C1TRPV1MGAMGAASI | |
| SCHEMBL2055567 | 0.81 | GPR119 (0.39) | NR3C1TRPV1MGAMGAASI | |
| SCHEMBL2087359 | 0.81 | MAP4K4 (0.42) | NR3C1GAAEPAS1MAPTDYRK1A | |
| SCHEMBL2085659 | 0.79 | BACE1 (0.39) | NR3C1MAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163759-B2 | Pyrazolo[1,5-A] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090258867-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258867-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | CNR1, CNR2, CCKAR | NR3C1 268/4885TRPV1 56/4885MGAM 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.